Noticias y Actividades de Crispr Therapeutics
Presencia
Crispr Therapeutics es una empresa que cotiza bajo el símbolo de cotización CRSP (CH).
Ejecutivos
Ver el organigrama con sus 19 ejecutivos principales
Biografías más buscadas en Crispr Therapeutics
- Samarth Kulkarni, Chief Executive Officer and Chairman of the Board
- Simeon George, Director
- Edd Fleming, Director
Recientes movimientos de ejecutivos en Crispr Therapeutics
- Julianne Bruno, Chief Operating Officer, abandonará la empresa el 26 de may.. de 2025 (noticia publicada el 27 de marzo de 2025).
- Briggs Morrison, se ha incorporado a la empresa como Director (noticia publicada el 8 de enero de 2025).
Crear su alerta
para seguir los movimientos de los ejecutivos en Crispr Therapeutics.
Biotecnología
Crispr Therapeutics tiene 2.347 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y Johnson & Johnson Innovative Medicine DIA (Estados Unidos).
Popular M&A news in Biotecnología
- Attovia Therapeutics acaba de anunciar una recaudación de fondos de 90 millones de dólares. (publicado el 21 de abril de 2025).
- Transcarent and Accolade have merged (publicado el 9 de abril de 2025)..
- Kashiv BioSciences acaba de anunciar una recaudación de fondos de 150 millones de dólares. (publicado el 7 de abril de 2025).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Crispr Therapeutics
- Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress | CRISPR Therapeutics
- CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress | CRISPR Therapeutics
- CRISPR Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference | CRISPR Therapeutics
- Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress | CRISPR Therapeutics
- CRISPR Therapeutics to Host Innovation Day on June 21, 2022 | CRISPR Therapeutics
- CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell Malignancies | CRISPR Therapeutics
- CRISPR Therapeutics Congratulates Co-Founder Emmanuelle Charpentier on Receiving the 2020 Nobel Prize in Chemistry | CRISPR Therapeutics
- CRISPR Therapeutics to Participate in Upcoming Investor Conferences | CRISPR Therapeutics
- CRISPR Therapeutics and Vertex Pharmaceuticals Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to CTX001™ for the Treatment of Sickle Cell Disease | CRISPR Therapeutics
- CRISPR Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference | CRISPR Therapeutics
- View more press releases Close
Redes sociales sobre Crispr Therapeutics
- Crispr Therapeutics en Wikipedia, Google News y Yahoo Finance
- Crispr Therapeutics en LinkedIn, Twitter y YouTube
